tetrapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-06. Numbers and descriptions here follow the published literature rather than marketing material.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
| Property | Value | Notes |
|---|---|---|
| Amino acid sequence | Ala-Glu-Asp-Gly | Tetrapeptide, often abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free peptide, unmodified termini |
| Molecular weight | ~390.35 Da | Calculated for the free acid form |
| Appearance | White to off-white powder | Typical lyophilized product form |
| Solubility class | Freely soluble in water | Two acidic residues dominate ionic character |
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
=== Receiver details === In addition to triggering the broadcast signal, the output of the transmitter trigger signal was also sent to the receiver hut. Here it fed the input to a time base generator that drove the X-axis deflection plates of the CRT display. This caused the electron beam in the tube to start moving left-to-right at the instant that the transmission was completed. Due to the slow decay of the pulse, some of the transmitted signal was received on the display. This signal was so powerful it overwhelmed any reflected signal from targets, which meant that objects closer than about 5 miles (8.0 km) could not be seen on the display. To reduce this period even to this point required the receiver to be hand-tuned, selecting the decoupling capacitors and impedance of the power supplies. The receiver system, built by A.C. Cossor to a TRE design, was a multiple-stage superheterodyne. The signal from the selected antennas on the receiver towers was fed through the radiogoniometer and then into a three-stage amplifier, with each stage housed in a metal screen box to avoid interference between the stages. Each stage used a Class B amplifier arrangement of EF8s, special low noise, "aligned-grid" pentodes. The output of the initial amplifier was then sent to the intermediate frequency mixer, which extracted a user-selectable amount of the signal, 500, 200 or 50 kHz as selected by a switch on the console. The first setting allowed most of the signal through, and was used under most circumstances.
In the 1830s, Jeremy Bentham, the founder of utilitarianism, left instructions to be followed upon his death which led to the creation of a sort of modern-day mummy. He asked that his body be displayed to illustrate how the "horror at dissection originates in ignorance"; once so displayed and lectured about, he asked that his body parts be preserved, including his skeleton (minus his skull, which despite being mis-preserved, was displayed beneath his feet until theft required it to be stored elsewhere), which were to be dressed in the clothes he usually wore and "seated in a Chair usually occupied by me when living in the attitude in which I am sitting when engaged in thought". His body, outfitted with a wax head created because of problems preparing it as Bentham requested, is on open display in the University College London.
=== Diet and meal timing === A Mediterranean-style eating pattern emphasizing vegetables, fruits, whole grains, legumes, nuts, and unsaturated fats—is associated with improvements in blood pressure, lipids, insulin sensitivity, and cardiovascular risk. Reduced-carbohydrate approaches may lower glucose and promote weight loss in insulin-resistant individuals. Evidence on meal timing suggests time-restricted eating or avoidance of late-night meals can modestly improve glycaemic and lipid markers, though long-term data are limited. Guidance recommends tailoring dietary advice to personal preference, culture, and access to improve adherence.
Sources: en.wikipedia.org
=== Inequalities === People living with AD and other forms of dementia and their unpaid carers might face inequalities in access to and the quality of care and support services. These inequalities can depend on various factors, including socio-economic background, housing situation, education level, gender, and race. People might have differences in how easily they can access AD services based on where they live. On a global level, people in low-and middle-income countries have fewer available facilities and services, and have greater difficulties accessing these than people living in high-income countries. As a result of AD and other forms of dementia being less recognised and treated in the healthcare systems of these countries, the level of awareness of AD as something caused by disease is relatively lower. At the same time, the local socio-cultural understandings of aging, senility, and eldercare may have larger effects on care provision and the reception of medical services. On a national level, people with AD might have unequal access to care based on where they live. This can manifest on a regional level, with people in rural areas facing more difficulties than those in urban areas. Inequalities can also affect smaller local units as well, for example people living in the same city might receive different or less frequent care based on their postcodes or the street they live in. Inequalities also affect people with AD from ethnic minority groups.
A target peptide is a short (3-70 amino acids long) peptide consensus sequence that directs the transport of a protein to a specific region in the cell, including the nucleus, mitochondria, endoplasmic reticulum (ER), chloroplast, apoplast, peroxisome and plasma membrane. Some target peptides are cleaved from the protein by signal peptidases after the proteins are transported.
Erythema annulare centrifugum (deep gyrate erythema, erythema perstans, palpable migrating erythema, superficial gyrate erythema) Erythema gyratum repens (Gammel's disease) Erythema migrans (erythema chronicum migrans) Erythema multiforme Erythema multiforme minor (herpes simplex-associated erythema multiforme) Erythema palmare Generalized erythema Necrolytic acral erythema Necrolytic migratory erythema (glucagonoma syndrome)
Sources: en.wikipedia.org
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.
No. Epitalon is chemically synthesized, not extracted. It was designed as a short synthetic fragment conceptually related to larger pineal peptides studied in the same research tradition, particularly the extract known as epithalamin. The two are distinct materials with different compositions.
The term bioregulator is used in this research tradition for short peptides proposed to influence gene expression or cell function. Epitalon is grouped with other synthetic short peptides under this label. The term reflects a proposed mechanism rather than an established drug classification.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.